MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MacroGenics reports revenue growth and promising clinical updates in Q4

MacroGenics delivered strong financial performance with revenue growth and cost reductions in 2022.
The company faces challenges in study modifications, dose optimization, and patient evaluation for its key products.
Opportunities lie in expanding product studies, strategic partnerships, and optimizing treatment efficacy.
Overall, MacroGenics shows promise in financial stability, product development, and market positioning.

MacroGenics reports Q1 revenue growth amidst net loss challenges

MacroGenics showed mixed financial performance in Q1 2023 with revenue growth but a significant net loss.
The company's strengths lie in its anticipated cash runway, FDA approvals, and expected milestone payments.
Challenges include managing expenses, improving financial performance, and addressing analyst inquiries.
Opportunities exist in revenue growth, clinical programs, FDA approvals, and strategic partnerships.

MacroGenics reports Q2 results, projects strong pipeline growth ahead

MacroGenics' Q2 2023 performance reflects mixed financial results but strong progress in pipeline development and strategic partnerships.
The company's financial stability, ongoing innovation, and revenue potential position it well for future growth and value creation.
Challenges in data disclosure, enrollment criteria, and dose optimization require careful navigation, but present opportunities for market expansion and program enhancement.

MacroGenics reports improved Q3 earnings, eyes strategic partnerships for growth

MacroGenics demonstrated improved financial performance in Q3 2023, with a focus on cost management and strategic pipeline advancements.
The company's efforts to secure non-dilutive capital, explore partnerships, and drive innovation in ADC development position it for future growth.
Challenges lie in revenue generation, market differentiation, and resource allocation, but opportunities exist in collaborations, tumor type expansion, and technological advancements.

MacroGenics reports revenue decline but advances in clinical programs

MacroGenics faced a decline in revenue but made progress in its clinical programs and pipeline advancements.
Challenges include data transparency, patient enrollment, and managing treatment side effects.
Opportunities lie in potential Phase III trials, revenue growth prospects, and advancements in patient treatment.

MacroGenics reports strong Q1 results, eyes expansion and combination therapies

MacroGenics' Q1 2024 performance showed promising results with strong revenue and ongoing research advancements.
The company's focus on expanding studies, improving tolerability, and exploring combination therapies presents growth opportunities.
Challenges include ongoing investigations into safety protocols and evaluation of patient outcomes.
Overall, MacroGenics' strategic plans and positive efficacy outcomes position them well for future growth and development.

MacroGenics reports stellar Q3 earnings, CEO transition announced

MacroGenics delivered impressive financial results in Q3 2024, marked by substantial revenue growth, increased net income, and a solid cash balance supported by strategic initiatives.
While facing challenges in managing rising expenses and navigating a CEO transition, the company's diverse clinical pipeline and strong financial position present opportunities for future growth and innovation.
Investors should monitor how MacroGenics addresses cost management, sustains operational momentum during leadership changes, and capitalizes on its strengths to drive continued success in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

The company provided a disappointing Q4 update.

Why MacroGenics Stock Is Sinking Today

MacroGenics, Inc. (MGNX) CEO Scott Canning on Q4 2021 Results - Earnings Call Transcript

MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates

ROCKVILLE, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2021.

MacroGenics Provides Update on Corporate Progress and 2021 Financial Results

ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2021 after the market closes on Thursday, February 24, 2022.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, February 24, 2022, at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 1067087.

MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call

Synaffix BV has entered into a technology agreement with MacroGenics Inc MGNX. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Synaffix, MacroGenics Ink Pact For Next Generation Antibody-Drug Conjugates

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q3 2021 Results - Earnings Call Transcript

MacroGenics (MGNX) delivered earnings and revenue surprises of -36.51% and -60.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q3 Loss, Misses Revenue Estimates

ROCKVILLE, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2021.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results

ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2021 after the market closes on Tuesday, November 2, 2021.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 2, 2021 at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 6063045.

MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call

The average of price targets set by Wall Street analysts indicates a potential upside of 69.5% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 69% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?

I-Mab

SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted the Company's IND application to initiate a phase 2 trial for enoblituzumab (also known as TJ271) in combination with pembrolizumab (Keytruda®) in patients with selected solid tumors in China.

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

MacroGenics Inc (NASDAQ: MGNX) announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was presented at the 2021 European Society for Medical Oncology (ESMO21) Virtual Conference.

MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation

ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data from dose expansion cohorts of the Company's ongoing Phase 1 clinical trial of MGC018. This investigational antibody-drug conjugate (ADC) was designed to deliver a DNA-alkylating duocarmycin payload to both dividing and non-dividing cells in a B7-H3-dependent manner. The dataset is being presented in a poster titled “MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion” (Poster #620P) at the 2021 European Society for Medical Oncology (ESMO) Virtual Conference taking place September 16-21, 2021.

MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress

ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of margetuximab. MARGENZA® (margetuximab-cmkb) is approved in HER2+ metastatic breast cancer and is being investigated as a potential first-line treatment for patients with HER2+ gastric cancer (GC) or gastroesophageal junction (GEJ) cancer in combination with a checkpoint inhibitor, with or without chemotherapy. The dataset is available in a poster titled “Margetuximab With Retifanlimab in HER2+, PD-L1+ First-Line Unresectable/Metastatic Gastroesophageal Adenocarcinoma (GEA): MAHOGANY Cohort A” (Poster #1379P) at the 2021 European Society for Medical Oncology (ESMO) Virtual Conference taking place September 16-21, 2021.

MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021

ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple investigational product candidates at the European Society for Medical Oncology (ESMO) Virtual Conference, taking place September 16-21, 2021.

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?

Investors are signaling hope in the company's top drug, despite a disappointing final analysis.

Why MacroGenics Soared Nearly 9% Higher Today

MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast cancer med Herceptin.  But Margenza's overall survival (OS) data could spell a rough road ahead for the drug.

MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis

MacroGenics Inc. MGNX, -3.20% shares were halted late Tuesday after the biotech drug developer said its breast-cancer treatment didn't perform as well as standard treatment in a late-stage clinical study. MacroGenics shares finished the regular session down 3.2% at $21.78.

MacroGenics study shows breast-cancer drug survival rates fell short

ROCKVILLE, MD, Sept. 07, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the final overall survival (OS) results of the SOPHIA Phase 3 study in adult patients with metastatic HER2-positive breast cancer. In 2020, MARGENZA (margetuximab-cmkb) was approved by the U.S. Food and Drug Administration (FDA) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The basis for this full approval was the progression-free survival (PFS) results in the SOPHIA study, which compared MARGENZA plus chemotherapy to trastuzumab plus chemotherapy in patients with metastatic HER2-positive breast cancer.

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer

Why MacroGenics Stock Is Tumbling Today

MacroGenics' (MGNX) CEO Scott Koenig on Q2 2021 Results - Earnings Call Transcript

ROCKVILLE, Md., July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2021.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for MacroGenics Stock (MGNX)